Floatz logo

CARMUSTINE

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

National Cancer Institute (NCI)Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2/3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2/3BB
Inno-206
National Cancer Institute (NCI)
Phase 2/3BB

View all 20 →

Same molecule, other indications

CARMUSTINE is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
74 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →